Exploring liquid biopsy genomic profiling for metastatic prostate cancer in Spain
Real World Clinical Practice Study to Assess the Feasibility and Impact of Liquid Biopsy-based Genomic Profiling on Treatment Decision Making for Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
This study is testing how analyzing blood and tumor samples can help doctors find better treatment options for men with advanced prostate cancer in Spain.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | SOLTI Breast Cancer Research Group Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Barcelona) |
| Trial ID | NCT05885009 on ClinicalTrials.gov |
What this trial studies
HOPE Prostate is an observational study focused on metastatic prostate cancer patients in Spain, utilizing a patient-centric approach. Participants will register voluntarily and provide blood samples and archival tumor biopsies, which will be genomically analyzed. A multidisciplinary molecular advisory board will review each case and provide reports detailing potential therapeutic options based on the genomic profiles. Patients will also complete follow-up questionnaires twice a year for three years to track their progress and experiences.
Who should consider this trial
Good fit: Ideal candidates include male patients aged 18 and older living in Spain with confirmed metastatic prostate cancer who are about to receive or are currently undergoing treatment.
Not a fit: Patients who are unable to consent or have conditions that compromise their safety or data quality may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance precision medicine approaches for managing metastatic prostate cancer, leading to more personalized treatment options.
How similar studies have performed: Other studies utilizing genomic profiling and patient-centric approaches have shown promise, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male patients living in Spain. 2. Age ≥18 years. 3. Signed informed consent before any screening procedure. 4. Metastatic PC of any subtype confirmed both pathologically and radiologically (stage IV disease). 5. The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the standard of care healthcare setting. 6. Eastern Cooperative Oncology Group (ECOG) 0-1. Exclusion Criteria: 1. Inability to consent or conform to the processes involved in a clinical study. 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where this trial is running
Barcelona
- SOLTI Cancer Research Group — Barcelona, Spain (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.